Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)

Next Previous
Trial Profile

Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms Botulinum toxin-A versus tolterodine for idiopathic overactive bladder; OVERT

Most Recent Events

  • 10 Sep 2018 Status changed from recruiting to completed.
  • 04 Dec 2015 Accrual to date is 15% according to United Kingdom Clinical Research Network record
  • 12 Nov 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top